US FDA approves Ultragenyx's gene therapy for rare disorder

The U.S. FDA approved Ultragenyx's gene therapy to treat a rare, fatal disease. The approval enables commercialization of a new therapy in a high-unmet-need indication and is a material positive catalyst for Ultragenyx, though no revenue or patient-population figures were provided.